Skip to content

Released Feb 28, 2013, after the close

10-K filed Feb 28, 2013, 59 days after period end · 0001144204-13-012065

Q4 2012 · 10-K

derived · Computed from the longer spans the company filed.

Revenue$1.17Mderived−50.4% vs Q4 2011−68.5% vs Q3 2012
Net Income-$9.88MderivedN/M vs Q4 2011N/M vs Q3 2012
EPS, diluted—Not derived. Share counts vary by quarter.
Gross Profitderived-$1,130,000N/M
Operating Incomederived-$10,167,000N/M
Operating Cash Flowderived$1,821,000N/M
Free Cash Flowderived$1,570,000N/M
Margins · derived
Gross margin-96.4%−108.9 pt vs Q4 2011
Operating margin-867.5%−492.5 pt vs Q4 2011
Net margin-842.7%−465.4 pt vs Q4 2011

What the release said

No earnings release is on file for this quarter. Its figures came with the 10-K.

Same quarter

MetricQ4 2012derived from reported figuresQ4 2011derived from reported figuresQ4 2010derived from reported figures
Revenue$1.17M$2.36M—
Net Income-$9.88M-$8.91M—

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Protalix BioTherapeutics, Inc. · CIK 1006281 · Engraved from SEC EDGAR